Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Small cell lung cancer16.19.08.003; 22.08.01.0130.000844%Not Available
Solar dermatitis23.03.09.0090.000651%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.003207%Not Available
Sputum discoloured22.02.03.010--Not Available
Sputum increased22.02.03.007--Not Available
Sudden death08.04.01.003; 02.03.04.0130.000362%
Sunburn23.03.09.007; 12.05.02.001--Not Available
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tearfulness19.15.02.0050.000362%Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.0030.000241%Not Available
Thrombosis24.01.01.006--Not Available
Tongue discolouration07.14.02.0060.000820%Not Available
Tongue oedema10.01.05.008; 07.14.02.007; 23.04.01.0090.000241%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000530%Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Transitional cell carcinoma20.08.01.010; 16.08.04.0020.000241%Not Available
Ulcer08.03.06.0010.001061%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Vasculitis24.12.04.027; 10.02.02.0060.000482%
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.0030.040989%
Weight decreased13.15.01.005--
Ischaemic cardiomyopathy02.04.01.004; 24.04.04.0190.000241%Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.001181%Not Available
Performance status decreased08.01.03.0420.000241%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 12 Pages